| CAS | 145781-92-6 |
| Sequence | Pyr-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azagly-NH2 |
| Sequence Single | pEHWSYs(tBu)LRP-Azagly-NH2 |
| Molecular Formula | C59H84N18O14 |
| Molecular Weight | 1269.43 |
| Synonyms | Goserelin, [DSer(tBu)6, (Aza)Gly10] LH-RH |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Cancer Research|Pituitary & Hypothalamic Hormones|Veterinary Medicine |
| Description | (D-Ser(tBu)6,Azagly10)-LHRH also called Goserelin, [DSer(tBu)6, (Aza)Gly10] LH-RH, a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer. |
| References | 1. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. D.C.Jackson et al., Proc. Natl. Acad. Sci. USA, 101, 15440 (2004) 2. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling. A.Wells et al., Clin. Cancer Res., 8, 1251 (2002) 3. Use of goserelin in the treatment of breast cancer. A.Rody et al., Expert Rev. Anticancer Ther., 5, 591 (2005) 4. No supra-additive effects of goserelin and radiotherapy on clonogenic survival of prostate carcinoma cells in vitro. Merck Index, 15th ed., No. 4562, (2013) |